Neptune Medical has successfully completed the spinout of its subsidiary, Jupiter Endovascular, following a substantial $97 million Series D financing round. Key participants in this funding included Sonder Capital and Olympus Corporation of the Americas, alongside contributions from various existing and new investors. This strategic financing aims to strengthen Neptune Medical’s focus on gastrointestinal robotics while empowering Jupiter Endovascular to concentrate on its innovative endovascular technology platform.
Alex Tilson, the Founder and CEO of Neptune Medical, expressed enthusiasm over the successful closure of the Series D financing and the spinout of Jupiter. He noted that these milestones allow Neptune to sharpen its focus on gastrointestinal robotics, which has the potential to improve patient care significantly. The support from investors underscores their confidence in Neptune’s vision and strategic direction.
Dr. Fred Moll, a pioneer in medical robotics, highlighted the strategic importance of Jupiter Endovascular’s spinout. He believes that this move aligns with long-term goals and positions Jupiter to drive innovation in endovascular therapies effectively. Meanwhile, Neptune Medical will continue to explore advancements in gastrointestinal robotics, aiming to deliver transformative solutions to both patients and healthcare providers.
Olympus Chief Strategy Officer Gabriela Kaynor also expressed excitement about participating in the financing round. She emphasized that Neptune’s innovative approach to endoscopy could significantly elevate the standard of care and improve patient outcomes. With dedicated resources for both Neptune Medical and Jupiter Endovascular, both entities are well-equipped to lead their respective fields in medical device innovation.
Reference:
